Patient-Reported Outcomes in T-Cell Lymphoma Trials

Document Type

Conference Proceeding

Publication Date

9-2025

Publication Title

Clinical Lymphoma, Myeloma and Leukemia

Abstract

Introduction: T-cell lymphomas represent 10%–15% of all nonHodgkin lymphomas, with an estimated 10,000 to 15,000 new cases annually in the US. Patient-reported outcome measures (PROMs) are increasingly used in clinical trials to complement traditional endpoints such as overall survival and progression-free survival. PROMs offer insight into patient-centered outcomes and inform both clinical decision-making and supportive care. We sought to examine trends in the inclusion of PROMs as outcome measures in clinical trials involving T-cell lymphomas. Methods: We conducted a systematic review of clinicaltrials.gov to identify completed phase 2, 3, and 4 clinical trials involving patients with T-cell lymphoma. Trials were included if they were marked as completed and had publicly available results. We screened each entry to determine whether PROMs were listed as either primary or secondary endpoints. Extracted variables included trial phase, date of completion, PROM usage, type of PROM tool used, and basic demographic characteristics of enrolled participants. Results: A total of 216 trials met inclusion criteria. Of these, only 7 trials (3%) incorporated PROMs as part of the reported outcomes, all of which listed them as secondary endpoints. The trials reporting PROMs were conducted between June 2012 and January 2024. Across these studies, the mean participant age was 59.4 years, and 54.9% of the participants were male. Ethnic distribution was predominantly White patients (64.3%), followed by Black patients (6.2%), and Asian patients (5.2%). A range of PROM instruments were employed, with Skindex-29 being the most commonly used (42.8%); followed by FACT-G, FACT-Lym, and EQ-5D (each used in 28.5% of studies); as well as EQ-5D-5L and EORTC QLQ-C30 (each in 14.2% of studies). Discussion: This study is the first to examine the use of PROMs in T-cell lymphoma trials, revealing that only 3% of completed phase 2–4 trials included PROMs exclusively as secondary outcomes. The wide variation in PROM tools limits comparability and weakens patient-centered assessment. These findings underscore the urgent need for standardized, validated PROM integration to ensure clinical trials capture outcomes that reflect patients’ lived experiences

Volume

25

Issue

Suppl 1

First Page

S878

Comments

Society of Hematologic Oncology Thirteenth Annual Meeting, September 3-6, 2025, Houston, TX

Last Page

S879

DOI

10.1016/S2152-2650(25)02525-X

Link to Full Text
Find in My Library

Share

COinS